334 related articles for article (PubMed ID: 19112391)
1. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.
Valis M; Talab R; Stourac P; Andrys C; Masopust J
Neuro Endocrinol Lett; 2008 Dec; 29(6):971-6. PubMed ID: 19112391
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis.
Terzi M; Birinci A; Cetinkaya E; Onar MK
Acta Neurol Scand; 2007 May; 115(5):325-30. PubMed ID: 17489943
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
4. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.
de Bont JM; Vanderstichele H; Reddingius RE; Pieters R; van Gool SW
Eur J Paediatr Neurol; 2008 Jul; 12(4):334-41. PubMed ID: 17951083
[TBL] [Abstract][Full Text] [Related]
5. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
6. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
8. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
9. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).
Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J
Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854
[TBL] [Abstract][Full Text] [Related]
10. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
11. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.
Bartosik-Psujek H; Archelos JJ
J Neurol; 2004 Apr; 251(4):414-20. PubMed ID: 15083285
[TBL] [Abstract][Full Text] [Related]
12. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP
Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581
[TBL] [Abstract][Full Text] [Related]
14. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
[TBL] [Abstract][Full Text] [Related]
15. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
16. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.
Brew BJ; Pemberton L; Blennow K; Wallin A; Hagberg L
Neurology; 2005 Nov; 65(9):1490-2. PubMed ID: 16275845
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
18. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
Wiltfang J; Esselmann H; Bibl M; Hüll M; Hampel H; Kessler H; Frölich L; Schröder J; Peters O; Jessen F; Luckhaus C; Perneczky R; Jahn H; Fiszer M; Maler JM; Zimmermann R; Bruckmoser R; Kornhuber J; Lewczuk P
J Neurochem; 2007 May; 101(4):1053-9. PubMed ID: 17254013
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
20. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
